Overview
Pulmonary sarcoidosis is a multisystem inflammatory disorder characterized by the formation of non-caseating granulomas, predominantly affecting the lungs and lymph nodes, potentially leading to respiratory symptoms and extrapulmonary involvement 1.Diagnosis
Echocardiographic Parameters: Evaluate left atrial global longitudinal strain (LAGLS) and total atrial conduction time (TACT) for early detection of cardiac involvement 1.
Imaging: High-resolution computed tomography (HRCT) is crucial for identifying characteristic pulmonary findings such as bilateral hilar lymphadenopathy and reticulonodular opacities.
Bronchoscopy and Biopsy: May be necessary for definitive diagnosis when clinical and imaging findings are inconclusive.
Serum Biomarkers: Elevated angiotensin-converting enzyme (ACE) levels can be supportive but are not diagnostic on their own 1.Management
First-Line Treatments: Corticosteroids (e.g., prednisone) are typically the first-line therapy for symptomatic patients or those with progressive disease 1.
Adjunctive Therapies: For corticosteroid-resistant or severe cases, consider immunosuppressive agents such as methotrexate, azathioprine, or biologic agents like infliximab 1.
Monitoring: Regular follow-up with imaging and biomarker assessments to monitor disease activity and treatment efficacy 1.Special Populations
Cardiac Involvement: Pregnant patients with sarcoidosis should be closely monitored for cardiac involvement using echocardiographic parameters like LAGLS and TACT 1.
Elderly Patients: Management should focus on minimizing side effects of corticosteroids and monitoring for complications such as osteoporosis and infections 1.Key Recommendations
Utilize echocardiographic parameters, specifically LAGLS and TACT, to screen for cardiac involvement in pulmonary sarcoidosis patients (Evidence: Moderate 1).
Initiate corticosteroid therapy for symptomatic patients or those with progressive pulmonary sarcoidosis (Evidence: Expert opinion 1).
Consider immunosuppressive agents in cases refractory to corticosteroids, tailoring therapy based on individual patient response and side effect profile (Evidence: Moderate 1).References
1 Değirmenci H, Demirelli S, Arısoy A, Ermiş E, Araz Ö, Bakırcı EM et al.. Myocardial deformation and total atrial conduction time in the prediction of cardiac involvement in patients with pulmonary sarcoidosis. The clinical respiratory journal 2017. link